Skip to main content
Clinical Trials/NL-OMON44441
NL-OMON44441
Not Yet Recruiting
N/A

A novel method to improve the detection of cancer and metastases by peptide scanning under the protection of enzyme inhibitors: PepProtect 1 - PepProtect 1

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
12
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Related to the medullary cancer of the thyroid:
  • 1\. Histologically documented medullary cancer of the thyroid (MTC), or with elevated tumour marker (serum calcitonin) after previous treatment(s) for MTC
  • Related to the patient:
  • 2\. Life expectancy of more than 6 months.
  • 3\. WHO performance status 0 or 1
  • 4\. Male or female patients aged \>18 years without upper age limit.

Exclusion Criteria

  • 1\. Patients requiring treatment of the tumour urgently, before assessments required for the study can be completed.
  • 2\. Pregnancy or breast feeding. Negative pregnancy test is required in female patients with child\-bearing potential.
  • 3\. Impaired renal function (eGFR \<60 mL/min/1\.73 m2\)
  • 4\. Impaired liver function (cirrhosis, grade B of the Child\-Pugh classification; or hepatic enzyme levels \>3x upper limit of normal)
  • 5\. Known allergy or hypersensitivity to gastrin analogues or any of the components of the study medications.
  • 6\. Any use of NEP\-inhibitors within 30 days prior to the study; any use of experimental medication or other medication that potentially interfere with racecadotril or In111\-DOTA\-MG11\.
  • 7\. Any use of ACE inhibitors within 3 days of racecadotril administrations.

Outcomes

Primary Outcomes

Not specified

Similar Trials